Skip to main
FHTX

Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Foghorn Therapeutics (FHTX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Foghorn Therapeutics Inc. is advancing its flagship program, FHD-909, which shows promising potential in treating serious diseases through innovative mechanisms targeting the chromatin regulatory system. The financial outlook appears favorable, with projections indicating a potential stock increase of 40-50% in the base case scenario and up to 60-90% in the bull case, depending on objective response rates (ORR) and duration of response (DoR). Additionally, FHD-909's demonstrated synergy with chemotherapy and checkpoint inhibitors suggests a robust efficacy, further enhancing the company’s growth prospects as it prepares for upcoming clinical expansions.

Bears say

Foghorn Therapeutics Inc. is facing significant challenges, as its internal clinical data failed to demonstrate a sufficient threshold of clinical benefit, potentially due to limitations related to its lead molecule, prompting a strategic pivot amid balance sheet constraints. Preclinical assessments have indicated that the efficacy of key compounds may be hindered by factors such as slow degradation kinetics and a notable hook effect, resulting in a limited response and durability of effect in clinical settings. Furthermore, the risk-adjusted valuation does not align favorably with market performance expectations, suggesting a potential decline of 30-40% based on current analyst projections.

Foghorn Therapeutics (FHTX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Foghorn Therapeutics (FHTX) Forecast

Analysts have given Foghorn Therapeutics (FHTX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Foghorn Therapeutics (FHTX) has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Foghorn Therapeutics (FHTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.